Targetable water-soluble polymer-drug conjugates for the treatment of visceral leishmaniasis

Journal of Controlled Release

Volumn 94, Issue 1, 2004, Pages 115-127

  Nan, Anjan ^a   Croft, Simon L ^b   Yardley, Vanessa ^b   Ghandehari, Hamidreza ^a,c  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF MARYLAND   (United States)

Author keywords

HPMA copolymers; Leishmania donovani; Phagolysosomes; Targeted drug delivery; Visceral leishmaniasis

Indexed keywords

CELLS; COPOLYMERS; DRUG DOSAGE; ENZYME INHIBITION; SYNTHESIS (CHEMICAL); TOXICITY; WATER;

MICROPHASES; WATER-SOLUBLE POLYMERS;

DRUG PRODUCTS;

8 AMINOQUINOLINE DERIVATIVE; 8 [4 (AMINO 1 METHYLBUTYL)AMINO] 5 (3,4 DICHLOROPHENOXY) 6 METHOXY 4 METHYLQUINOLINE; ANTIPROTOZOAL AGENT; MANNOSAMINE; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; NPC 1161; UNCLASSIFIED DRUG;

AMASTIGOTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL STRAIN KB; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG CONJUGATION; DRUG EFFICACY; DRUG SCREENING; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; LEISHMANIA DONOVANI; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTOZOAL INFECTION; VISCERAL LEISHMANIASIS;

EID: 0347365761     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2003.09.012     Document Type: Article

References (30)

1. WHO/CDS/CSR/ISR/2000. 1 Leishmaniasis and Leishmania/HIV co-infection. WHO report on global surveillance of epidemic prone infectious diseases, 2001.
2. Murray H.W. Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches. Int. J. Infect. Dis. 4:2000;158-177.
3. Mauel J. Intracellular survival of protozoan parasites with special reference to Leishmania spp. Toxoplasma gondii, and Trypanosoma cruzi. Adv. Parasitol. 38:1996;1-51.
4. Banerjee G., Nandi G., Mahato S.B., Pakrashi A., Basu M.K. Drug delivery system: targeting of pentamidines to specific sites using sugar grafted liposomes. J. Antimicrob. Chemother. 38:1996;145-150.
5. Baillie A.J., Coombs G.H., Dolan T.F., Hunter C.A., Laakso T., Sjoholm I., Stjarnkvist P. Biodegradable microspheres: polyacryl starch microparticles as a delivery system for the antileishmanial drug, sodium stibogluconate. J. Pharm. Pharmacol. 39:1987;832-835.
6. Paul M., Durand R., Boulard Y., Fusai T., Fernandez C., Rivollet D., Deniau M., Astier A. Physicochemical characteristics of pentamidine-loaded polymethacrylate nanoparticles: implication in the intracellular drug release in Leishmania major infected mice. J. Drug Target. 5(6):1998;481-490.
7. Paul M., Durand R., Fessi H., Rivollet D., Houin R., Astier A., Deniau M. Activity of a new liposomal formulation of amphotericin B against two strains of Leishmania infantum in a murine model. Antimicrob. Agents Chemother. 41(8):1997;1731-1734.
8. Golenser J., Frankenburg S., Ehrenfreund T., Domb A.J. Efficacious treatment of experimental leishmaniasis with amphotericin B-arabinogalactan water-soluble derivatives. Antimicrob. Agents Chemother. 43(9):1999;2209-2214.
9. Nan A., Nanayakkara N.P.D., Walker L.A., Yardley V., Croft S.L., Ghandehari H. N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers for targeted delivery of 8-aminoquinoline antileishmanial drugs. J. Control. Release. 77(3):2001;233-243.
10. Raay B., Medda S., Mukhopadhyay S., Basu M.K. Targeting of piperine intercalated in mannose-coated liposomes in experimental leishmaniasis. Indian J. Biochem. Biophys. 36(4):1999;248-251.
11. Green P.J., Feizi T., Stoll M.S., Thiel S., Prescott A., McConville M.J. Recognition of the major cell surface glycoconjugates of Leishmania parasites by the human serum mannan-binding protein. Mol. Biochem. Parasitol. 66:1994;319-328.
12. Kopecek J., Kopeckova P., Minko T., Lu Z.R. HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur. J. Pharm. Biopharm. 50(1):2000;61-81.
13. Rathi R.C., Kopeckova P., Rihova B., Kopecek J. N-(2-hydroxypropyl) methacrylamide copolymers containing pendant saccharide moieties: synthesis and bioadhesive properties. J. Polym. Sci., A, Polym. Chem. 29:1991;1895-1902.
14. J. Kopecek, P. Rejmanova, J. Strohalm, K. Ulbrich, B. Rihova, V. Chytry, J.B. Lloyd, R. Duncan, Synthetic polymeric drugs. US Patent. 5,037 883 (1991).
15. Van de Loo H.M. An improved method for the quantitative determination of hexosamines according to Elson and Morgan. Anal. Biochem. 76(2):1976;556-560.
16. Neal R.A., Croft S.L. An in vitro system for determining the activity of compounds against the intracellular amastigote form of Leishmania donovani. J. Antimicrob. Chemother. 14:1984;463-475.
17. Asres K., Bucar F., Knauder E., Yardley V., Kendrick H., Croft S.L. In vitro antiprotozoal activity of extract and compounds from the stem bark of combretum molle. Phytother. Res. 15:2001;613-617.
18. Egan B.S., Lane K.B., Shepherd V.L. Nucleotide PU.1 and USF are required for macrophage-specific mannose receptor promoter activity. J. Biol. Chem. 274(13):1999;9098-9107.
19. Yardley V., Croft S.L. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis. Int. J. Antimicrob. Agents. 13(4):2000;243-248.
20. Rihova B., Rathi R.C., Kopeckova P., Kopecek J. In vitro bioadhesion of carbohydrate-containing N-(2-hydroxypropyl)methacrylamide copolymers to the GI tract of guinea pigs. Int. J. Pharm. 87:1992;105-116.
21. Seymour L.W., Duncan R., Strohalm J., Kopecek J. Effect of molecular weight (Mw) of N-(2-hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to rats. J. Biomed. Mater. Res. 21(11):1987;1341- 1358.
22. Kopecek J., Bazilova H. Poly[N-(2-hydroxypropyl)methacrylamide]: 1. Radical polymerization and copolymerization. Eur. Polym. J. 9:1973;7-14.
23. Kayser O., Kiderlen A.F., Laatsch H., Croft S.L. In vitro leishmanicidal activity of monomeric and dimeric naphthoquinones. Acta Trop. 77:2000;307-314.
24. Ashwell G., Harford J. Carbohydrate-specific receptors of the liver. Annu. Rev. Biochem. 51:1982;531-554.
25. Kayser O., Kiderlen A.F., Bertels S., Siems K. Antileishmanial activities of Aphidicolin and its semisynthetic derivatives. Antimicrob. Agents Chemother. 45(1):2001;288-292.
26. L.M. Werbel, E.A. Steck, Antileishmanial lepidine derivatives. US Pat. 4, 659, 708 (1987).
27. Monkkonen J., Taskinen M., Auriola S.O., Urtti A. Growth inhibition of macrophage-like and other cell types by liposome-encapsulated, calcium-bound, and free bisphosphonates in vitro. J. Drug Target. 2(4):1994;299-308.
28. Pennanen N., Lapinjoki S., Urtti A., Monkkonen J. Effect of liposomal and free bisphosphonates on the IL-1 beta, IL-6 and TNF alpha secretion from RAW 264 cells in vitro. Pharm. Res. 12(6):1995;916-922.
29. Colton C.A., Czapiga M., Snell-Callanan J., Chernyshev O.N., Vitek M.P. Apolipoprotein E acts to increase nitric oxide production in macrophages by stimulating arginine transport. Biochim. Biophys. Acta. 1535(2):2001;134-144.
30. Ylitalo R., Jaakkola O., Lehtolainen P., Yla-Herttuala S. Metabolism of modified LDL and foam cell formation in murine macrophage-like RAW 264 cells. Life Sci. 64(21):1999;1955-1965.